| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/30/1996 | US5512590 Prevents disorder of gabaergic transmission |
| 04/30/1996 | US5512581 Antiinflammatory agent |
| 04/30/1996 | US5512580 Method and compositions for maintaining glomerular filtration rate while inhibiting extracellular matrix accumulation |
| 04/30/1996 | US5512579 Aminobenzoic acid derivatives |
| 04/30/1996 | US5512578 Administering bimodally-acting opioid agonist and excitatory opioid receptor antagonist |
| 04/30/1996 | US5512576 2-substituted 1,2,5,-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof |
| 04/30/1996 | US5512574 Treating neurological and mental illnesses, such as alzheimer's |
| 04/30/1996 | US5512573 Skin irritation; prevention transplant rejection |
| 04/30/1996 | US5512569 Aminoalkyl benzothiazolinones |
| 04/30/1996 | US5512566 Useful in treating diseases of central nervous system |
| 04/30/1996 | US5512563 Tricyclic benzazepine vasopressin antagonists |
| 04/30/1996 | US5512562 Tricyclic 2,3,4,5-tetrahydro-1H-3-benzapines |
| 04/30/1996 | US5512552 Bone resorption inhibitor; osteoporosis |
| 04/30/1996 | US5512550 Method for inhibiting angiogenesis with modified platelet factor-4 and cleaved platelet factor-4 |
| 04/30/1996 | US5512460 Glia activating factor and its production |
| 04/30/1996 | US5512459 Transpeptization by contacting peptide and addition unit with thrombin to cleave leaving unit from core at enzyme cleavage site |
| 04/30/1996 | US5512442 Using specific antibody binding |
| 04/30/1996 | US5512303 Injectable pharmaceutical composition |
| 04/30/1996 | US5512270 Respiratory system disorders, parkinson's disease, gastrointestinal disorders |
| 04/29/1996 | CA2154543A1 Human 26s proteasome subunit components |
| 04/27/1996 | CA2161399A1 Package for a veterinary implant |
| 04/25/1996 | WO1996011951A2 Keratinocyte growth factor analogs |
| 04/25/1996 | WO1996011950A1 Method of treating diabetes mellitus using kgf |
| 04/25/1996 | WO1996011949A2 Analogs of keratinocyte growth factor |
| 04/25/1996 | WO1996011948A1 Neurotrophic peptides of activity dependent neurotrophic factor |
| 04/25/1996 | WO1996011934A1 Tricyclic spiro compounds process for their preparation and their use as 5ht1d receptor antagonists |
| 04/25/1996 | WO1996011933A1 Fused pyrrolocarbazoles |
| 04/25/1996 | WO1996011925A1 Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4' (ltb4) antagonists |
| 04/25/1996 | WO1996011922A1 Pyrrolyl tetrahydrobenzoquinoxaline diones, their preparation and use as glutamate receptor antagonists |
| 04/25/1996 | WO1996011911A1 5-lipoxygenase inhibitors |
| 04/25/1996 | WO1996011902A1 Pharmaceutically active substituted aromatic compounds |
| 04/25/1996 | WO1996011698A1 Allosteric modulators of the nmda receptor |
| 04/25/1996 | WO1996011697A1 Thrombin inhibitors |
| 04/25/1996 | WO1996011690A1 Diazepino-indoles as phosphodiesterase iv inhibitors |
| 04/25/1996 | WO1996011688A1 Use of zaprinast for the manufacture of a medicament for inhibiting vascular restenosis |
| 04/25/1996 | WO1996011685A2 Use of indole derivatives for the treatment of various diseases |
| 04/25/1996 | WO1996011676A1 Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases |
| 04/25/1996 | WO1996011671A1 Targeted delivery via biodegradable polymers |
| 04/25/1996 | WO1996011664A2 Nsk2 a muscle receptor tyrosine kinase |
| 04/25/1996 | CA2202630A1 Use of zaprinast for the manufacture of a medicament for inhibiting vascular restenosis |
| 04/25/1996 | CA2202511A1 Targeted delivery via biodegradable polymers |
| 04/25/1996 | CA2202056A1 Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4' (ltb4) antagonists |
| 04/25/1996 | CA2201527A1 Pyrrolyl tetrahydrobenzoquinoxaline diones, their preparation and use as glutamate receptor antagonists |
| 04/25/1996 | CA2200628A1 Diazepino-indoles as phosphodiesterase iv inhibitors |
| 04/25/1996 | CA2161176A1 Heterocyclic compounds and their preparation and use |
| 04/24/1996 | EP0708103A1 Process for the preparation of a tetrazole derivative in two crystalline forms and a new crystalline form of this derivative |
| 04/24/1996 | EP0708101A1 Novel piperidine derivatives, useful as neurokinin receptor antagonists |
| 04/24/1996 | EP0708099A1 Tricyclic amide compounds, process for their preparation and pharmaceutical compositions containing them |
| 04/24/1996 | EP0707850A1 Use of polyunsaturated fatty acids for the manufacture of a medicament for the treatment of brest pain |
| 04/24/1996 | EP0707849A1 Use of derivatives of 2,4-bisubstituted phenols as 5-lipoxigenase inhibitors |
| 04/24/1996 | EP0707848A1 Solid pharmaceutical composition comprising an excipient capable of binding water |
| 04/24/1996 | EP0707595A1 Peptidase resistant thrombin receptor peptide ligand |
| 04/24/1996 | EP0707585A1 Bicyclic tetrahydro pyrazolopyridines |
| 04/24/1996 | EP0707579A1 Piperidinyl substituted methanoanthracenes as d1/d2-antagonists and 5ht2-serotanin-antagonists |
| 04/24/1996 | EP0707577A1 Heme binding compounds and use thereof |
| 04/24/1996 | EP0707566A1 Novel structural analogues of vitamin d |
| 04/24/1996 | EP0707495A1 Compositions for treating hypoxia-associated ocular complications |
| 04/24/1996 | EP0707490A1 Neuropeptide y antagonists and agonists |
| 04/24/1996 | EP0707475A1 Extended release, film-coated tablet of astemizole and pseudoephedrine |
| 04/24/1996 | EP0609371B1 Thienopyrazine-2,3-diones useful for treating cns disorders, and their preparation. |
| 04/24/1996 | EP0573562B1 Dihydroquinoline NMDA antagonists |
| 04/24/1996 | CN1121348A Indole derivatives as 5-H1-like agonists for use in migraine |
| 04/24/1996 | CN1121345A New compounds |
| 04/24/1996 | CN1121344A New compounds |
| 04/24/1996 | CN1121072A Acetamides |
| 04/23/1996 | US5510480 Certain azacycloalkyl imidazopyrimidines: a new class of GABA brain receptor ligands |
| 04/23/1996 | US5510462 IL-1βprotein precursor |
| 04/23/1996 | US5510387 Antimicrobial interferon-inducing medicament |
| 04/23/1996 | US5510385 Analgesics, antiinflammatory agents |
| 04/23/1996 | US5510370 Osteoporosis, osteoarthritis treatment |
| 04/23/1996 | US5510367 Indole derivatives |
| 04/23/1996 | US5510359 Heteroaromatic 5-hydroxytryptamine receptor agonists |
| 04/23/1996 | US5510343 Bicyclic and tricyclic β-lactams |
| 04/23/1996 | US5510339 Method for the treatment of bronchial asthma by administration of topical anesthetics |
| 04/23/1996 | US5510333 Inhibitors of Cathepsin G and elastase for preventing connective tissue degradation |
| 04/23/1996 | US5510331 Antihypertensive peptides |
| 04/23/1996 | US5510239 One of the intersugar linkages between nuclotide units of the oligonuclotide is phosphorothioate linkage |
| 04/23/1996 | US5510104 Administering a selective alpha-amino acids or their alkyl esters in presence of halide; microbiocides; myeloperoxidase, eosinophil peroxidase |
| 04/18/1996 | WO1996011209A1 Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases |
| 04/18/1996 | WO1996011206A1 Process for preparing 17-beta-substituted-androsta-3,5-dien-3-carboxylic acids |
| 04/18/1996 | WO1996011195A1 Indole derivatives as 5ht1-like agonists |
| 04/18/1996 | WO1996011192A1 Lta4 hydrolase inhibitors |
| 04/18/1996 | WO1996011021A2 Treatment of tissues to reduce subsequent response to injury |
| 04/18/1996 | WO1996011020A1 Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient |
| 04/18/1996 | WO1996011006A1 5-ht1f mediated inhibition of neurogenic meningeal extravasation |
| 04/18/1996 | WO1996010999A2 Lta4 hydrolase inhibitor pharmaceutical compositions and methods of use |
| 04/18/1996 | WO1996010912A1 Method for reducing unwanted cellular adhesions |
| 04/18/1996 | WO1996010910A1 Method and formulation of stimulating nitric oxide synthesis |
| 04/18/1996 | WO1996005288A3 T cell activation |
| 04/18/1996 | DE4436852A1 Pyrrolyl-tetrahydrobenzochinoxalindione, ihre Herstellung und Verwendung Pyrrolyl tetrahydrobenzochinoxalindione, their preparation and use |
| 04/18/1996 | CA2202371A1 Lta4 hydrolase inhibitors |
| 04/18/1996 | CA2202368A1 Lta4 hydrolase inhibitor pharmaceutical compositions and methods of use |
| 04/18/1996 | CA2202272A1 Treatment of tissues to reduce subsequent response to injury |
| 04/18/1996 | CA2201639A1 Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases |
| 04/17/1996 | EP0707006A1 Aroyl-piperidine derivatives |
| 04/17/1996 | EP0707004A1 1-Arylalcenyl 4-arylmethylpiperazinderivatives, process for their preparation and pharmaceutical composition containing them |
| 04/17/1996 | EP0706799A2 Immunoconjugates II |
| 04/17/1996 | EP0706795A2 Catechol diether compounds as inhibitors of TNF release |
| 04/17/1996 | EP0706793A2 Use of phthalidyliden esters of carnitine and alkanoyl carnitines for the treatment of endotoxic shock |
| 04/17/1996 | EP0706568A1 Vertebrate apoptosis gene: compositions and methods |